PUBLISHER: The Business Research Company | PRODUCT CODE: 1951603
PUBLISHER: The Business Research Company | PRODUCT CODE: 1951603
The cervical cancer vaccine is a vaccine specifically designed to prevent the development of cervical cancer by targeting high-risk types of human papillomavirus (HPV) that are responsible for the majority of cervical cancer cases. These vaccines work by stimulating the body's immune system to produce antibodies that can identify and neutralize the HPV virus.
The primary types of cervical cancer vaccines include Cervarix, Gardasil, and Gardasil 9. Cervarix is a cervical cancer vaccine used to provide protection against specific strains of human papillomavirus (HPV) that are known to cause cervical cancer. These vaccines are distributed through channels such as hospital pharmacies, retail pharmacies, and online pharmacies, and are supplied to various end users, including hospitals, biotechnology companies, academic and research organizations, and others.
Tariffs have affected the cervical cancer vaccine market by increasing the cost of imported vaccine components and raw materials, which has led to higher production expenses and limited availability in certain regions. The impact is most significant on vaccines like Gardasil and Cervarix, particularly in Asia-Pacific and African markets that rely on imports. While tariffs may slow market growth temporarily, they also encourage local manufacturing initiatives and strategic sourcing, which could enhance regional self-sufficiency and long-term market stability.
The cervical cancer vaccine market research report is one of a series of new reports from The Business Research Company that provides cervical cancer vaccine market statistics, including cervical cancer vaccine industry global market size, regional shares, competitors with a cervical cancer vaccine market share, detailed cervical cancer vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the cervical cancer vaccine industry. This cervical cancer vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The cervical cancer vaccine market size has grown strongly in recent years. It will grow from $92.33 billion in 2025 to $99.14 billion in 2026 at a compound annual growth rate (CAGR) of 7.4%. The growth in the historic period can be attributed to increasing prevalence of hpv infections, early introduction of hpv vaccines, government immunization campaigns, rising cervical cancer awareness, availability of vaccination infrastructure.
The cervical cancer vaccine market size is expected to see strong growth in the next few years. It will grow to $135.87 billion in 2030 at a compound annual growth rate (CAGR) of 8.2%. The growth in the forecast period can be attributed to advancements in vaccine technology, expansion of vaccination coverage in developing regions, public-private partnerships for immunization, introduction of single-dose hpv vaccines, increasing healthcare expenditure on preventive care. Major trends in the forecast period include expansion of hpv vaccination programs, rising awareness about cervical cancer prevention, development of next-generation hpv vaccines, government and ngo initiatives for immunization, collaborations between pharmaceutical and biotech companies.
The increasing prevalence of cervical cancer cases is anticipated to drive the growth of the cervical cancer vaccine market in the coming years. Cervical cancer is a form of cancer that affects the lower portion of the uterus, known as the cervix, which connects the uterus to the upper part of the vagina. The rise in cervical cancer incidence is largely attributed to inadequate vaccination against human papillomavirus (HPV), poor hygiene practices, and limited awareness and understanding of cervical cancer. Cervical cancer vaccines are highly effective in preventing the disease by targeting high-risk strains of HPV. For example, in January 2023, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, 13,960 cervical cancer cases were reported in the United States. Consequently, the growing number of cervical cancer cases is contributing to the expansion of the cervical cancer vaccine market.
Leading companies involved in cervical cancer vaccines are increasingly emphasizing collaborations and partnerships to deliver dependable solutions to patients. A strategic partnership refers to a formal relationship between two or more businesses, typically established through contractual agreements to achieve shared objectives. For instance, in June 2023, Nykode Therapeutics ASA, a Norway-based next-generation vaccine developer, announced an expansion of its collaboration with Roche Holding AG to advance VB10.16, an off-the-shelf therapeutic cancer vaccine. Under this collaboration, VB10.16 is expected to be evaluated in combination with Roche's immunotherapy in patients with advanced cervical cancer. This partnership has the potential to lead to the development of a new and effective treatment option for cancers that currently have limited therapeutic alternatives and poor prognoses.
In March 2024, Halma PLC, a UK-based technology company, acquired Rovers Medical Devices for €85 million. This acquisition aims to strengthen Halma PLC's presence in the women's health segment, particularly in cervical cancer diagnostics. Rovers Medical Devices is a Netherlands-based manufacturer known for its self-sampling device that incorporates built-in features to ensure proper sample collection and provide reassurance to women.
Major companies operating in the cervical cancer vaccine market are Merck & Co Inc, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Beijing Wantai Biological Pharmacy Enterprise Co Ltd, Walvax Biotechnology Co Ltd, Xiamen Innovax Biotech Co Ltd, THERAVECTYS, ViciniVax, Recbio, Yuxi Zerun Biotech, BioVaxys Technology Corp, Procare Health Iberia SL, R-Pharm LLC, PathoVax LLC, PT Biofarma, Instituto Butantan, Sinergium Biotech, CSL Limited, UCB SA, Bharat Biotech International Ltd
North America was the largest region in the cervical cancer vaccine market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cervical cancer vaccine market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the cervical cancer vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The cervical cancer vaccine market consists of sales of a gardiquimod, V503, silgard, and Human papillomavirus vaccines. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Cervical Cancer Vaccine Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses cervical cancer vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for cervical cancer vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cervical cancer vaccine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.